Chimeric antigen receptor-modified (CAR)-T cells have demonstrated impressive results in the treatment of haematological malignancies. However, cytokine release syndrome (CRS) and neurotoxicity are common toxicities which are potentially life-threatening in severe cases. Risk factors for CRS and neurotoxicity identified so far include disease burden, lymphodepletion intensity and CAR-T cell dose administered. Risk-adapted dosing, with lower CAR-T cell doses administered to B-cell acute lymphoblastic leukaemia patients with high marrow blast counts, has been successful at decreasing severe CRS rates in this population. Intervention with therapies, such as tocilizumab and corticosteroids, have been effective at ameliorating toxicity, enabling CAR-T cells to be administered safely to many patients without significantly compromising efficacy. Deeper understanding of the pathophysiology of underlying CRS and neurotoxicity will enable the development of novel approaches to reduce toxicity and improve outcomes.
Background
The discovery of a T cell-mediated graft-versus-leukaemia effect that contributed to the prevention of relapse after allogeneic haematopoietic cell transplantation provided evidence that the adaptive immune system plays a significant role in the surveillance and eradication of malignant cells (Horowitz et al, 1990) . In the decades since this discovery, T cell engaging immunotherapies targeting malignancies have undergone a rapid pace of innovation. Harnessing the anti-tumour activity of T cells using bi-specific T cell engaging molecules (BiTEs) or chimeric antigen receptor-modified (CARÀ) T cells has demonstrated significant potential for the treatment of haematological malignancies (Brentjens et al, 2013; Grupp et al, 2013 Grupp et al, , 2015 Davila et al, 2014; Maude et al, 2014a Maude et al, , 2018 Lee et al, 2015; Ali et al, 2016; Turtle et al, 2016a,b,c; Kantarjian et al, 2017; Locke et al, 2017; Neelapu et al, 2017a) .
In particular, the CD19-targeting BiTE, blinatumomab, and CD19 CAR-T cells have demonstrated incredible success in heavily pre-treated B-cell malignancies. In B-cell acute lymphoblastic leukaemia (ALL), the complete remission (CR) rate after blinatumomab was reported to be 44%, with 34% of treated patients achieving minimal residual disease (MRD)-negative CR (Kantarjian et al, 2017) . Impressive MRD-negative CR rates of 63-93% were observed after CD19 CAR-T cell therapy in B-cell ALL Davila et al, 2014; Maude et al, 2014a Maude et al, , 2018 Lee et al, 2015; Turtle et al, 2016a; Park et al, 2018a) . Although blinatumomab has had only a modest effect in non-Hodgkin lymphoma (NHL), with a CR rate of 19% reported in a phase I study, CR rates of >40% have been reported after CD19 CAR-T cells (Kochenderfer et al, , 2017 Turtle et al, 2016b; Viardot et al, 2016; Neelapu et al, 2017a; Schuster et al, 2017a) . Successes of CD19 CAR-T cell therapy have also been seen in chronic lymphocytic leukaemia, with overall response rates of 57-74% Turtle et al, 2017) .
Subsequently, both blinatumomab and CAR-T cells specific to CD19 have received approval from the US Food and Drug Administration (FDA), with blinatumomab and tisagenlecleucel approved for the treatment of relapsed/refractory ALL, and tisagenlecleucel and axicabtagene ciloleucel approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma. The success of CD19-specific T cellengaging therapies has also led to rapid increase in the number of preclinical studies and clinical trials exploring this approach further, with different targets, such as CD20 for NHL, B cell maturation antigen (BCMA) for multiple myeloma, and CD123 for acute myeloid leukaemia (Till et al, 2008; Gill et al, 2014; Cohen et al, 2017) . As of the date of this review, over 280 clinical trials involving CAR-T cell therapy are registered as actively recruiting patients (clinicaltrials.gov).
However, similar to the discovery of graft-versus-host disease after allogeneic haematopoietic cell transplantation, T cell-engaging therapies have also been associated with specific toxicities; namely cytokine release syndrome (CRS) and neurotoxicity. CRS is a supraphysiological immune system activation marked by fever and increased production and release of cytokines such as interferon-c (IFN-c), tumour necrosis factor-a (TNFa), interleukin (IL) 2, IL6, IL8, IL10, soluble IL2 receptor a (IL2Ra), macrophage inflammatory protein 1a (MIP-1a, also termed CCL3) and monocyte chemoattractant protein 1 (MCP1; also termed CCL2) into the circulation and tissues, leading to vascular instability, macrophage activation syndrome and end-organ toxicity in severe cases (Teachey et al, , 2016 Lee et al, 2014; Maude et al, 2014a; Kochenderfer et al, 2015; Turtle et al, 2016a; Locke et al, 2017) . Neurological toxicity, although closely associated with CRS, can manifest as a multitude of different neurological adverse events, and can even occur after the successful treatment and resolution of CRS Santomasso et al, 2018a,b) .
Although both blinatumomab and CAR-T cells have been associated with CRS and neurotoxicity, the different mechanisms of action lead to significant differences in the clinical presentation and management of these toxicities. Administered as a continuous infusion (due to its very short halflife), blinatumomab can be held at signs of toxicity and appropriate management steps taken. Re-treatment with blinatumomab even after severe CRS has been successfully managed (Marini et al, 2018) . CAR-T cells, on the other hand, are a 'living-drug' that proliferates and expands in vivo, and the risks of toxicity treatment must be balanced with the risk of impairing the anti-tumour efficacy of the CAR-T cells.
This review aims to highlight the clinical presentation, grading and management of CRS, and neurotoxicity secondary to CAR-T cell therapy, our current understanding of the pathophysiology of both CRS and neurotoxicity, and potential ways to improve CAR-T cell therapy by decreasing toxicity. Our current understanding of CRS and neurotoxicity derives mainly from experience with CD19 CAR-T cells; therefore, this review will focus on toxicities following this therapy, with the hope that the lessons we learn from targeting CD19 may help inform CAR-T cell strategies targeting other antigens.
Clinical presentation of CRS
CRS occurs in around 70% of patients after CD19 CAR-T cell therapy, with published incidence rates ranging from 35% to 93%, depending on the product infused and disease treated (Table I; Neelapu et al, 2017a; Schuster et al, 2017a; Maude et al, 2018; Park et al, 2018a; Teachey et al, 2016; Abramson et al, 2018) . Fever with or without constitutional symptoms is the first objective sign of CRS, and temperatures >39°C are common (Teachey et al, 2016; . Rarely does CRS occur without fever and it is typically mild in these cases, consisting mainly of flu-like symptoms (Teachey et al, 2016; . Onset of CRS is approximately 1-6 days after CAR-T cell infusion, with >95% of CRS events occurring before 12 days after CAR-T cell infusion. Late onset CRS after day 12 following CAR-T cell infusion has been known to occur but is often non-severe in these cases . Common laboratory abnormalities include evidence of an inflammatory response, with elevations of C-reactive protein and ferritin Davila et al, 2014; Teachey et al, 2016; .
Severe CRS occurs in 12-47% patients after CD19 CAR-T cell therapy, according to the grading system used for the CAR-T cell product infused Locke et al, 2017; Neelapu et al, 2017a; Schuster et al, 2017a,b; Maude et al, 2018; Park et al, 2018a) . Fever in patients with severe CRS presents earlier after CAR-T cell infusion, peaks earlier, reaches a higher maximum temperature, and is of longer duration . Patients who subsequently develop severe CRS often do not present with severe symptoms at the time of fever onset; rather, severe symptoms manifest a few days afterwards. Symptoms and signs of severe CRS can vary significantly between patients and the CAR-T cell product infused; however, there are some common themes (Lee et al, 2015; Neelapu et al, 2017b; Teachey et al, 2018) . Most patients with moderate to severe CRS initially show evidence of vascular instability with tachycardia, hypotension and hypoalbuminaemia, which is initially responsive to fluids or low doses of vasopressors. However, those with very severe CRS subsequently progress to hypotension requiring high dose vasopressors, capillary leak syndrome and multiorgan failure (Fitzgerald et al, 2017; .
Organ toxicities in CRS include, but are not limited to: liver failure with elevated serum aspartate aminotransferase, alanine aminotransferase and bilirubin levels; acute kidney injury with increased serum creatinine levels and decreased urine output; cardiac complications with arrhythmias, heart block and low ejection fraction; respiratory issues with pleural effusions, pulmonary oedema and hypoxic respiratory failure; and neurological adverse events, which will be discussed further below. Assessment of organ toxicity secondary to CRS requires thorough evaluation for other aetiologies, such as worsening of pre-existing comorbidities and the possibility of progressive disease. CRS has also been seen to exacerbate pre-existing organ comorbidities; for example, children treated with CAR-T cells who had pre-existing diastolic dysfunction or baseline low ejection fraction were more likely to develop hypotension-requiring inotropic support secondary to CRS (Burstein et al, 2018) .
Haematological effects of severe CRS include worsening persistent cytopenias with delayed haematopoietic recovery and coagulopathy (Teachey et al, 2016; . More transfusion support is required in patients with severe CRS, and the marrow biopsy can often reveal a hypocellular marrow . Patients with severe CRS can have prolongation of the prothrombin and activated partial thromboplastin times early after CAR-T cell infusion, which is followed later by laboratory evidence of disseminated intravascular coagulation, with increasing D-dimer and falling fibrinogen concentrations. The nadir of fibrinogen often occurs around 1-2 weeks after CAR-T cell infusion .
In addition to fever, cytopenias and hypofibrinogenaemia, a profound rise in the serum ferritin, soluble CD25, and cytokines, such as IFN-c and IL6, in severe CRS suggests many similarities to macrophage activation syndrome/haemophagocytic lymphohistiocytosis (MAS/ HLH). Indeed, many patients with moderate to severe CRS would meet the diagnostic criteria for MAS/HLH (Teachey et al, 2018) . Despite the similarities between severe CRS and MAS/HLH, caution is warranted in equating the two, given the potential differences in aetiology and management of each disorder.
Increasing severity of CRS has also been associated with infections after CAR-T cell therapy, independent of neutropenia. In a study using multivariable modelling, CRS severity was the only significant risk factor for infection (Hill et al, 2018) . Supporting this, another study using a different CD19 CAR-T cell product also demonstrated an increase in infections, particularly bloodstream infections with severe CRS .
Clinical presentation of neurotoxicity
As mentioned above, neurological adverse events are a unique toxicity after CAR-T cell therapy. Although neurotoxicity occurs almost exclusively in patients with some degree of CRS, there are rare exceptions of neurological adverse events without CRS, which, together with its separate timing and onset after CAR-T cell infusion, suggests that neurotoxicity should be considered separately from CRS.
Neurological adverse events after CD19 CAR-T cell therapy have been seen to occur in 32-64% of patients Neelapu et al, 2017a; Schuster et al, 2017a; Maude et al, 2018; Park et al, 2018a; Santomasso et al, 2018b) . Onset of neurotoxicity is approximately 5-7 days after CAR-T cell infusion, often during CRS or after CRS has resolved Maude et al, 2018; Santomasso et al, 2018b) . The severity of neurotoxicity correlates strongly with the severity of CRS, but severe neurotoxicity has been known to occur in some patients after only a mild episode of CRS Maude et al, 2018; Santomasso et al, 2018b) . Grade ≥3 neurotoxicity by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 (https:// www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_Quic kReference_5x7.pdf) occurs in 11-42% of patients, depending on the type of disease treated and the CAR-T cell product infused Neelapu et al, 2017a ; Schuster Table I . Cytokine release syndrome and neurotoxicity rates in published CD19 CAR-T cell trials. AEs, adverse events; ALL, acute lymphoblastic leukaemia; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukaemia; CRS, cytokine release syndrome; CTCAE, common terminology criteria for adverse events; MSKCC, Memorial Sloan Kettering Cancer Center; NHL, non-Hodgkin lymphoma.
et al, 2017a; Maude et al, 2018; Park et al, 2018a; Santomasso et al, 2018b) . Manifestations of neurotoxicity following CAR-T cell infusion can vary widely. Mild to moderate symptoms include headache, tremor, mild aphasia, mild movement disorders and encephalopathy or delirium with preserved alertness. Waxing and waning of neurological symptoms can occur. This toxic encephalopathy with preserved alertness is one of the more common presentations, and is marked by diminished attention, disorientation, confusion and/or language disturbances Neelapu et al, 2017b; Santomasso et al, 2018b) . In more severe cases, focal neurological deficits can develop as well as generalized tonic/clonic seizures; in very severe cases, coma, intracranial haemorrhage and a fatal rapid onset diffuse cerebral oedema can result Neelapu et al, 2017b; Santomasso et al, 2018b) .
Magnetic resonance imaging (MRI) and computed tomography scans of the brain are typically negative, even in patients with an apparent focal neurological deficit on physical examination. In a study at our institution, acute abnormalities on brain MRI were seen in only 30% of patients with neurotoxicity, but an abnormal scan was associated with a higher risk of a poor outcome, suggesting that MRI may be useful to obtain in patients with severe neurotoxicity . T2-weighted-fluid-attenuated inversion recovery (T2/FLAIR) changes consistent with vasogenic oedema, leptomeningeal enhancement and/or multifocal microhaemorrhages were seen in the majority of these cases. Focal FLAIR hyperintensities can also present without evidence of focal neurological deficits. On electroencephalogram (EEG), the most common finding in patients with neurotoxicity was diffuse slowing Santomasso et al, 2018a,b) . In a few patients, non-convulsive status epilepticus has been detected Santomasso et al, 2018b) . Cerebral spinal fluid (CSF) analysis during acute neurotoxicity has been noted to demonstrate higher protein concentrations and leucocyte counts compared to prior to lymphodepletion. CAR-T cells are often detected in the CSF, however, the absolute number or percentage of CAR-T cells in the CSF does not appear to correlate with the severity of neurotoxicity Neelapu et al, 2017b; Santomasso et al, 2018b) .
Toxicity grading systems
Early on in single centre trials of CD19 CAR-T cell therapy, investigators quickly identified that the CTCAE grading for CRS, which was devised for CRS occurring during infusion of a drug, did not adequately describe the delayed and prolonged CRS seen after CAR-T cell therapy Lee et al, 2014) . In addition, there was concern that early therapeutic interventions for CRS might be detrimental to CAR-T cell expansion and persistence. This led to different modified grading systems being proposed, of which three main different grading systems are currently in use and described in Table II .
Although most experts in the field agree on the definition of CRS, many factors have contributed to the lack of consensus on a grading system to use for CRS, as well as the best management practice depending on severity (Davila et al, 2014; Lee et al, 2014; Maude et al, 2014b; Neelapu et al, 2017b Neelapu et al, , 2018 Porter et al, 2018; Teachey et al, 2018) . Underlying disease (ALL versus NHL) and age (paediatric versus adult) are just two of the factors that can impact CRS management and grading. For example, patients with ALL have higher rates of CRS and are more prone to developing severe neurotoxicity compared to NHL patients Teachey et al, 2018) . In addition, children may be less likely to develop long-term morbidity from CRS compared to adults, suggesting there may be a different threshold for intervention (Teachey et al, 2018) .
Neurological adverse events are graded accordingly to the CTCAE standards with one exception, called the CAR-T cellrelated encephalopathy syndrome (CRES) grading system (Neelapu et al, 2017b) . This system relies on the assessment of a non-validated scoring system (CARTOX-10) to evaluate the degree of loss of normal cognitive function, determination of intracranial pressure, and the presence of seizures or motor weakness. Validation in an independent cohort is warranted to determine whether this grading system is more useful than the CTCAE system in assessing CAR-T cell-related neurotoxicity.
The most important factor suggesting that universal grading may not currently be feasible is that different CAR constructs and T cell manufacturing processes are associated with different rates of toxicity and manifestations. Different costimulatory signal domains (such as CD28 versus 4-1BB [also termed TNFRSF9]) appear to significantly alter CAR-T cell proliferation, expansion and persistence kinetics (Brentjens et al, 2013; Lee et al, 2015; Kawalekar et al, 2016) . In a comprehensive study of neurotoxicity after 19-28z CAR-T cell therapy for adult patients with B-cell ALL at one institution, 42% of patients experienced severe neurotoxicity, with seizures developing in 16 (72%) of these severe cases (Santomasso et al, 2018b) . In contrast, severe neurotoxicity in adult patients with a 4-1BB CAR-T cell product at our institution was 30%, with only 4 (29%) of these patients developing seizures, 2 of whom had an antecedent seizure history . These results suggest that significant differences exist between CAR-T cell products, which warrants further investigation.
Risk factors and pathophysiology of CRS and neurotoxicity

Risk factors
After infusion, CAR-T cells migrate to the bone marrow, lymph nodes and tissues, where they recognize their cognate antigen and undergo rapid proliferation and expansion (Turtle & Riddell, 2011; Turtle et al, 2012; Turtle, 2014; . Development of both CRS and neurotoxicity appear to be tightly associated with this process of CAR-T cell antigen recognition and proliferation, as severity of CRS is associated with factors significantly impacting in vivo CAR-T cell expansion, such as disease burden, intensity of lymphodepleting chemotherapy regimen and the CAR-T cell dose administered (Lee et al, 2014; Park et al, 2018a) . In addition, pre-existing neurological comorbidities are associated with a higher risk of CAR-T cell-related neurotoxicity .
Pathophysiology
Our understanding of the pathophysiology of CRS and neurotoxicity continues to evolve, with many mechanisms not yet fully elucidated. Despite the association between CAR-T cell expansion and toxicity, recently published preclinical data using xenogeneic mouse models also suggests that monocytes/macrophages play a key role in the development of both CRS and neurotoxicity (Singh et al, 2017; Giavridis et al, 2018; Norelli et al, 2018) . In a severe combined immunodeficiency (SCID)/beige mouse model of CRS induced by ErbB-specific CAR-T cell therapy, macrophage depletion prior to adoptive cell transfer ameliorated toxicity (van der Stegen et al, 2013) . In humanized mice with high leukaemia burden, human monocytes were the predominant source of IL1 and IL6 during CRS. Blockade of the IL6 receptor (IL6R) with tocilizumab prevented CRS, but neurotoxicity still developed; however, blocking IL1 with the IL1 receptor (IL1R) antagonist, anakinra, prevented both CRS and neurotoxicity (Norelli et al, 2018) . In a separate study, SCID/beige mice grafted with high tumour burden intraperitoneally developed CRS, with murine macrophages being the major source of IL6 (Giavridis et al, 2018) . Similar to the study of humanized mice, blockade in this study with an anti-murine IL6R antibody or with anakinra prevented CRS in these mice (Giavridis et al, 2018) . Importantly, in both studies, the use of IL1 or IL6 blockade did not blunt the anti-tumour efficacy of the CAR-T cells. IL1 release preceded IL6 production by hours and is known to induce secretion of IL6, suggesting that IL1 initiates IL6 release. Indeed, in the mice treated with anakinra, both IL1 and IL6 levels were significantly lower, suggesting anakinra blocks the cascade of cytokine release at earlier stage (Norelli et al, 2018) . After these initiating events of CAR-T cell antigen engagement and monocyte/macrophage activation, cytokine release exposes the vascular endothelium to high serum levels of endothelium-activating cytokines, such as IL6 and IFN-c (Pober, 1988; Maruo et al, 1992) . In severe CRS, evidence of endothelial activation can be seen, with high serum concentrations of von Willebrand factor (VWF) and angiopoietin-2, which are released from the Weibel-Palade bodies on endothelial activation . Free serum angiopoietin-2 can then displace angiopoietin-1, which favours endothelial quiescence, from the endothelial TIE2 receptor, leading to further endothelial activation and microvascular permeability (Page & Liles, 2013) . Autopsy performed in one patient who succumbed to refractory hypotension due to CRS revealed, by dual in situ hybridization, that endothelial cells in the setting of CRS also produce IL6, suggesting another positive feedback mechanism leading to increased endothelial activation (Obstfeld et al, 2017) . Such systemic endothelial activation and microvascular permeability have been shown to induce systemic capillary leak syndrome, with clinical symptoms of hypotension and hypoalbuminaemia, similar to CRS (Xie et al, 2012) .
IL6 has also been shown to disrupt the blood-brain barrier (BBB) endothelium in vitro with decreased expression of intracellular tight junction molecules (Blecharz-Lang et al, 2018) . Endothelial activation and increased permeability at the level of the BBB would then expose the underlying pericytes embedded in the basal lamina to the high levels of cytokines in the serum. Pericytes, along with endothelial cells, play a central role in maintaining BBB integrity and are critical for the formation of tight junctions (Armulik et al, 2010; Daneman et al, 2010; Obermeier et al, 2013; Hall et al, 2014) . When human-derived pericytes were incubated in vitro with similar concentrations of IFN-c to those seen in severe CRS, increased IL6 and vascular endothelial growth factor (VEGF) production, and decreased platelet-derived growth factor receptor-b expression (a marker of pericyte stress) were seen. Additionally, pericyte exposure to TNF-a also increased IL6 production .
This in vitro evidence of BBB disruption is further supported by autopsy studies in patients who developed severe CRS and neurotoxicity that progressed to a fatal cerebral oedema Torre et al, 2018) . Histological evidence of endothelial activation and BBB permeability were identified in one patient, with platelet aggregation and VWF binding in small capillaries, perivascular CD8 + T cell infiltration, vascular wall destruction and multifocal haemorrhage . In a separate report of a patient who developed fatal cerebral oedema, perivascular exudates with fibrin deposition and endothelial damage appeared secondary to BBB disruption (Torre et al, 2018) . Furthermore, in a recently described rhesus macaque model of CRS and neurotoxicity after CD20 CAR-T cell infusion, disproportionately high CSF levels of IL6, IL2, granulocyte-macrophage colonystimulating factor, and VEGF were seen in animals with neurotoxicity (Taraseviciute et al, 2018) . In the macaques with neurotoxicity, pan-T cell encephalitis, with multifocal perivascular T cell cuffing was seen, similar to the autopsy data (Taraseviciute et al, 2018) .
Management of CRS and neurotoxicity
Different management algorithms for CRS and neurotoxicity exist, and the variety of different algorithms is reflected by the different CAR-T cell trials and products in existence (Lee et al, 2014; Neelapu et al, 2017b; Porter et al, 2018) . Common to all algorithms is symptomatic management for mild CRS symptoms. If the CAR-T cell product was administered as an outpatient, hospitalization at onset of fever is suggested for monitoring. In addition, patients are often still neutropenic from the lymphodepleting chemotherapy at the time of CRS onset, and it can be difficult to differentiate CRS from febrile neutropenia. Therefore frequently empiric antibiotics for febrile neutropenia are prescribed and filgrastim can be considered (Neelapu et al, 2017b; Teachey et al, 2018) . Mild hypotension can typically be treated with fluids alone; however, hypotension requiring vasopressor should warrant CRS-directed therapies. Although the optimal approach to treating CRS remains unknown, anti-IL6 therapy and/or corticosteroids have demonstrated success.
Anti-IL6 therapy
The early observation in CAR-T cell trials, that CRS is accompanied by an elevation of IL6, led investigators to try tocilizumab, a monoclonal antibody that blocks the IL6R . Although there were initial concerns that tocilizumab may impair CAR-T cell anti-tumour activity, there does not appear to be any evidence that this is the case. Use of tocilizumab is now standard of care in CRS, and it received FDA approval for this indication in August 2017 based on a retrospective analysis of CRS after tisagenlecleucel and axicabtagene ciloleucel (Le et al, 2018) . In this analysis, around 70% of patients responded to 1-2 doses of tocilizumab within 14 days, with a median time to response of 4 days. Response was defined as lack of fever and no vasopressors for 24 h. The majority of patients who responded did so within 7 days. Although the optimal dose and re-dosing schedule of tocilizumab for CRS is undefined, the typical dose used is 8 mg/kg. Review of pharmacokinetic data suggest that 8 mg/kg dosing every 8 h for up to 4 doses would be safe according to previous observations, although repeat dosing after 6 h has been suggested in severe cases (Neelapu et al, 2017b; Le et al, 2018) . Typical timing of repeat dosing is every 12-24 h until the severity of CRS symptoms decrease.
To date, no adverse events have been reported following the administration of tocilizumab for CRS. Most patients with CRS requiring intervention will receive only 1-2 doses of tocilizumab, and it is unlikely that any significant long-term toxicities will develop. When tocilizumab is given chronically for rheumatological diseases, side effects have included transaminitis, thromobocytopenia, lipid abnormalities and a modest increase in infections. Neutropenia is the only significant dose-related toxicity, which resolves with discontinuation of the agent (Grange et al, 2011; Shovman et al, 2015) .
One major limitation of tocilizumab is that it does not appear to significantly cross the BBB, and patients who have had resolution of CRS after tocilizumab administration can still develop neurotoxicity Maude et al, 2018) . After IL6R blockade with tocilizumab, IL6 levels in the serum continue to rise, which could lead to ongoing exposure of the brain parenchyma to IL6. In a non-human primate preclinical model, intravenous administration of tocilizumab provided minimal central nervous system (CNS)/CSF exposure to the drug, whereas intraventricular administration increased the CSF concentration of tocilizumab by approximately 85-fold (Nellan et al, 2018) . However, it is currently unclear if intraventricular administration in patients would be helpful to reduce neurotoxicity severity.
Siltuximab is an anti-IL6 monoclonal antibody that is FDA-approved for the management of multicentric Castleman disease, and currently used off label for the treatment of CRS (Deisseroth et al, 2015) . Siltuximab has a theoretical benefit of being able to block IL6 directly, and thus prevent exposure of the CNS to the high IL6 levels seen after tocilizumab administration, potentially leading to lower neurotoxicity. This has led to some experts suggesting algorithms where tocilizumab or siltuximab are equally interchangeable (Neelapu et al, 2017b (Neelapu et al, , 2018 . Others argue, however, that in the absence of clinical trials comparing the two agents, siltuximab should be considered as third line therapy, after tocilizumab and corticosteroids, given the known benefit of tocilizumab use (Teachey et al, 2018) .
Corticosteroids
Corticosteroids are an obvious choice for the treatment of CRS given their potent anti-inflammatory properties. Steroids in the setting of BiTEs in vitro have been shown to reduce cytokine levels without affecting T cell activation (Brandl et al, 2007) . However, given the potential cytotoxicity to T cells and subsequent effect on efficacy, corticosteroids are typically reserved for cases that are not responsive to anti-IL6 blockade. In addition, steroids are frequently used when neurotoxicity is encountered, given the lack of responsiveness to tocilizumab alone. Given its good CNS penetration, dexamethasone is a logical choice, though methylprednisolone is also used with good success. The precise dosing and scheduling of corticosteroids is still debated (Neelapu et al, 2017b; Teachey et al, 2018) .
Preventing and decreasing severe toxicity
As we gain a better understanding of the risk factors for the unique toxicities following CD19 CAR-T cell therapy, better approaches to reduce the incidence and severity of CRS and neurotoxicity have been developed. An example of this is risk-adapted dosing in B-cell ALL, with lower CAR-T cell doses used in patients with higher marrow burden of disease. This approach appears to be effective at reducing toxicity while maintaining efficacy (Turtle et al, 2016a; . In addition, an early intervention strategy soon after onset of CRS using tocilizumab appears to be successful without compromising efficacy rates (Gardner et al, 2016) . Algorithms that incorporate clinical signs with biomarkers could also aid in identifying patients at risk of severe CRS early on after CAR-T cell infusion, providing an opportunity to identify those patients who would most benefit from early intervention (Teachey et al, 2016; . However, any algorithm for toxicity prediction currently is experimental, and it is unclear if they would be applicable across different CAR-T cell products.
The pathophysiology of CRS and neurotoxicity elucidated from pre-clinical models suggest that IL1 blockade with anakinra may reduce both CRS and neurotoxicity, although this approach has yet to be tested in a clinical trial. Given the timing of IL1 and IL6 release, anakinra would probably be most effective early on in the development of CRS, or even as a prophylactic agent. In addition, in inflammatory myopathies, anakinra has been seen to favour the development of T-helper celltype 1 CD4 + T cells, potentially aiding in antitumour efficacy (Zong et al, 2014) . These factors, combined with the favourable safety profile of anakinra, make this an attractive option for CRS and neurotoxicity treatment and prevention (den Broeder et al, 2006) . In cases of severe toxicity not responding to therapy, a novel approach is to perform ablation of the T cells using an inducible Caspase 9 system or antibody-based approach targeting a molecule on the CAR-T cell, such as cetuximab for epidermal growth factor receptor-tagged (EGFR+) CAR-T cells (Wang et al, 2011; Zhou et al, 2015; Paszkiewicz et al, 2016; Tasian et al, 2017) . However, this would potentially have a serious effect on efficacy, and it is currently unclear if ablation of the CAR-T cells after the development of severe symptoms would be beneficial. Another approach that would potentially preserve the anti-tumour efficacy would be an inducible gene-regulatory system "on switch" approach, whereby the expression or signalling of the CAR is controlled by drug administration, allowing for the CAR to be downregulated in the setting of severe toxicity (Sakemura et al, 2016) .
Conclusion
CRS and neurotoxicity after CAR-T cell therapy are significant toxicities that need to be managed appropriately. Improvements in understanding the presentation, risk factors and management of CRS have been effective at ameliorating toxicity, enabling CAR-T cells to be administered safely to many patients. Predictive modelling of severe CAR-T cellrelated toxicities should be refined in larger cohorts with external validation, with a goal to guide early interventions. Further clinical trials will be necessary to determine the optimal combination and timing of therapies, as well as the best approach to treating neurotoxicity.
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